Loxo Oncology Inc. (NASDAQ:LOXO) saw unusually-high trading volume on Tuesday . Approximately 277,711 shares changed hands during mid-day trading, an increase of 176% from the previous session’s volume of 100,674 shares.The stock last traded at $25.24 and had previously closed at $25.07.

A number of equities analysts recently weighed in on LOXO shares. Stifel Nicolaus restated a “buy” rating and set a $36.00 price objective on shares of Loxo Oncology in a research report on Monday, April 18th. Zacks Investment Research upgraded Loxo Oncology from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research report on Saturday, July 9th. Cowen and Company restated a “buy” rating on shares of Loxo Oncology in a research report on Wednesday, July 13th. Finally, Oppenheimer Holdings Inc. restated an “outperform” rating and set a $30.00 price objective on shares of Loxo Oncology in a research report on Tuesday, April 19th. Five analysts have rated the stock with a buy rating, Loxo Oncology has an average rating of “Buy” and a consensus price target of $29.60.

The stock’s market capitalization is $497.43 million. The stock’s 50 day moving average is $24.41 and its 200 day moving average is $23.09.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.10. Equities research analysts anticipate that Loxo Oncology Inc. will post ($2.40) earnings per share for the current year.

In other news, major shareholder Aisling Capital Iii Lp purchased 232,558 shares of the business’s stock in a transaction dated Tuesday, May 17th. The shares were acquired at an average price of $21.50 per share, with a total value of $4,999,997.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

An institutional investor recently bought a new position in Loxo Oncology stock. GSA Capital Partners LLP purchased a new stake in shares of Loxo Oncology Inc. (NASDAQ:LOXO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 37,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,055,000. GSA Capital Partners LLP owned about 0.22% of Loxo Oncology as of its most recent SEC filing.

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.